TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight Change (Percent of Initial Body Weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Participants With Weight Loss ≥ 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median PFS according to RECIST 1.1 criteria on afatinib treatment (first-line cohort)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median PFS according to RECIST 1.1 criteria on afatinib treatment (second or later line cohort)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life assessment by EORTC QLC-30 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stable blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain measurement during injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of autologous e-ASC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: security of autologous e-ASC
Endpoint domain: Adverse events/effects
Primary endpoint: Relative Clinical Attachment Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Nottingham Health Profile (NHP)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement of eye moisturising and motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of O-desmethyltramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of weaning from mechanical invasive ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkles profilometry (Ra - micrometers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-gD antibody titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Who Reported Positive Effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Benzodiazepine withdrawal severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of High Threshold Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-Exit From Current Study Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in complete blood count (CBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects experiencing adverse events through 18 months
Endpoint domain: Adverse events/effects
Primary endpoint: overall duration of antibiotic therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in walking distance to onset of leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in walking distance to maximal leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Outcomes Study Pain Effects Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Gait measured by 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance measured by 25-foot walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative requirement for additional uterotonic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Final diagnoses of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With rSBA-MenC, rSBA-MenA, rSBA-MenW-135, rSBA-MenY Titers ≥ Cut-off Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-measles Antibody Concentrations ≥ Cut-off Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-mumps Antibody Concentrations ≥ Cut-off Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-rubella Antibody Concentrations ≥ Cut-off Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the average one year neck pain intensity (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in the average one year back pain intensity (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in the one year prevalence of neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MAGE and injection score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1C and injection score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SDBG and injection score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DW-MRI: ADC change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total spinal 'hole' volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total spine 'collapse' volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSA: trabecular wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of local recurrence at the hepatico-duodenal ligament
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete abortions without surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Fasting Brain Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of inserted osmotic dilators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total time taken for cervical priming with Dilapan-S/Dilasoft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoxia Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of LBC for diagnosis of Bilio-pancreatic tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause mortality rate on day 30
Endpoint domain: Mortality/survival
Primary endpoint: Poor neurocognitive outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trauma Symptom Checklist-40 (TSC-40)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Calcitonin Gene-Related Peptide (CGRP) Levels in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nerve Growth Factors (NGF) Levels in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of HAT and other NTDs/IDs
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Reporting Any Form of Sexual Violence Perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Paracentesis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change of eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of Urine TP/Cr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of serum hsCRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of urine TGF-beta/Cr level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of PK parameters for eltrombopag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drainage stay duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change From Baseline in Morning Pre-dose (Trough) FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Standardized Uptake Values (SUVRs) of Florbetaben
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized Uptake Values (SUVRs) of 18F-MK-6240
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychological flexibility abilities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Left Ventricular Circumferential Strain change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: residual platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tidal breathing carbon dioxide waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete resections in the postoperative MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Diagnosis of PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressiveness of PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success or failure of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Who Achieved a PASI 75 Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving a PGA of Cleared (0) or Minimal (1) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of Eyes With IOP Lowering Rate of 20% or More From Baseline up to Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: accuracy value for %SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SEEG recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete occlusion of aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retreatment of aneurysm
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Significant event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Egg reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: The level of Immunoglobulin (Ig) A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The level of Immunoglobulin (Ig) G
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The level of Immunoglobulin (Ig) M
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with adverse events due to biopsies
Endpoint domain: Adverse events/effects
Primary endpoint: Number of successful xenografts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Engraftment rate compared to clinical data
Endpoint domain: Mortality/survival
Primary endpoint: Difference in ENG plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HF re-admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of immune seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: awareness rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Liver fat percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RT-PCR confirmed RSV hospitalization from birth to 1 year
Endpoint domain: Mortality/survival
Primary endpoint: RT-PCR confirmed RSV hospitalization from birth to 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Major complications (≥ grade IIIa)
Endpoint domain: Adverse events/effects
Primary endpoint: ACR20 responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement of lipid profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of inflammatory profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Probability of weaning from oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes of waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of blood triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes of blood high-density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes of blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Soluble P-selectin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentration of known biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urgent coronary revascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: End-of-treatment Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Desensitization to allergic food
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunological change in IgG4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Communication at 1 Year
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: NNNS Excitability Score at Term Equivalent Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with abnormal serum sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: eye alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of neovascular tissues in disc-diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose
Endpoint domain: Physiological/clinical
Primary endpoint: Proportion of women delivering at a health facility
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Forced Expiratory Volume in 1 Second (L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Carbon Monoxide Diffusing Capacity (mL/Min/mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Glucose homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Youth Enrolled in Substance Use Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Youth Enrolled in Any Behavioral Health Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) of Melphalan
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-14d
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reaction time variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities associated with treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing adverse events (AEs) / serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing adverse events (AEs) leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: average knee index pain with walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in NYHA-class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain measured with VAS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Norepinephrine (NE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Epinephrine (E)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Trinity amputation and prosthesis scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bowel Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sexual Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary Health, Irritative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary Health, Obstructive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Confidence in Symptom Self-Management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Online Patient Satisfaction Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Net Promotor Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of trivalent split influenza vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Response Rate at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of recanalization (TIMI/TICI grade II or III flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major complications (vessel perforation, intramural arterial dissection, symptomatic intra-cranial hemorrhage, significant embolization)
Endpoint domain: Adverse events/effects
Primary endpoint: Gait analysis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported change in alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Discontinuing Study Medication Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial Performance Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dP/dT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bile IgG4 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroscan test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Clinical stage at time of presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients compliant with treatment plan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of treatment completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of TPN (total parenteral nutrition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Magnitude of rebound pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARR positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PA confirmed diagnostic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The change of office blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The rate of incidence of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients making a second appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of admissions to hospital or emergency room
Endpoint domain: Resource use
Endpoint subdomain: Hospital